---
provider: openscientist
model: openscientist-autonomous
cached: false
start_time: '2026-08-31T07:44:31.007906'
end_time: '2026-08-31T08:05:54.047229'
duration_seconds: 1283.04
template_file: templates/disease_pathophysiology_research.md
template_sha: "1e7ea4ee817acfe1dda5f77fafe6f2e8b5927666"
template_variables:
  disease_name: Brachyolmia-Amelogenesis Imperfecta Syndrome
  mondo_id: ''
  category: Mendelian
provider_config:
  timeout: 3600
  max_retries: 3
  parameters:
    allowed_domains: []
    max_iterations: 5
    use_hypotheses: false
    investigation_mode: autonomous
    poll_interval: 30
    timeout: 3600
    save_artifacts: true
    artifact_max_bytes: 5242880
citation_count: 17
reference_validation:
  total_references: 17
  verified: 17
  not_found: 0
  unverifiable: 0
  confabulation_rate: 0.0
  quotes_checked: 28
  quotes_valid: 28
  relevance_assessed: 17
  on_topic: 9
  validator_version: 0.2.1
term_validation:
  total_terms: 35
  verified: 34
  not_found: 0
  obsolete: 0
  unverifiable: 1
  confabulation_rate: 0.0
  labels_checked: 10
  labels_matching: 7
  labels_mismatched: 1
  mislabelled_terms:
  - term_id: HP:0012865
    reported_labels:
    - Broad femoral neck
    ontology_label: Abnormal sperm head morphology
  labels_variant: 2
  needs_review: true
  adapter: 'ols:'
  validator_version: 0.4.5
artifact_count: 2
artifact_sources:
  openscientist_artifacts_zip: 2
artifacts:
- filename: final_report.html
  path: Brachyolmia-Amelogenesis_Imperfecta_Syndrome-deep-research-openscientist_artifacts/final_report.html
  media_type: text/html
  source: openscientist_artifacts_zip
  data_storage_id: null
  description: OpenScientist final report
- filename: final_report.pdf
  path: Brachyolmia-Amelogenesis_Imperfecta_Syndrome-deep-research-openscientist_artifacts/final_report.pdf
  media_type: application/pdf
  source: openscientist_artifacts_zip
  data_storage_id: null
  description: OpenScientist final report
---

## Question

# Disease Characteristics Research Template

## Target Disease
- **Disease Name:** Brachyolmia-Amelogenesis Imperfecta Syndrome
- **MONDO ID:**  (if available)
- **Category:** Mendelian

## Research Objectives

Please provide a comprehensive research report on **Brachyolmia-Amelogenesis Imperfecta Syndrome** covering all of the
disease characteristics listed below. This report will be used to populate a disease knowledge
base entry. Be thorough and cite primary literature (PMID preferred) for all claims.

For each section, **suggested databases/resources** are listed. These are the first places
you should search for information on each topic.

---

### 1. Disease Information
> **Search first:** OMIM, Orphanet, ICD-10/ICD-11, MeSH, PubMed

- What is the disease? Provide a concise overview.
- What are the key identifiers? (OMIM, Orphanet, ICD-10/ICD-11, MeSH, Mondo)
- What are the common synonyms and alternative names?
- Is the information derived from individual patients (e.g., EHR) or aggregated disease-level resources?

### 2. Etiology

- **Disease Causal Factors**: What are the primary causes? (genetic, environmental, infectious, mechanistic)
- **Risk Factors**:
  > **Search first:** PubMed, Cochrane Library, UpToDate, clinical guidelines, ClinVar, ClinGen, GWAS Catalog, PheGenI, CTD, CDC, WHO, epidemiological databases
  - Genetic risk factors (causal variants, susceptibility loci, modifier genes)
  - Environmental risk factors (toxins, lifestyle, occupational exposures, age, sex, family history)
- **Protective Factors**:
  > **Search first:** PubMed, Cochrane Library, clinical trial databases, GWAS Catalog, gnomAD, WHO, CDC, nutrition databases
  - Genetic protective factors (protective variants, modifier alleles)
  - Environmental protective factors (diet, lifestyle, exposures that reduce risk)
- **Gene-Environment Interactions**: How do genetic and environmental factors interact to influence disease?
  > **Search first:** CTD, PubMed, PheGenI, GxE databases

### 3. Phenotypes
> **Search first:** HPO (Human Phenotype Ontology), OMIM, Orphanet, PubMed, clinicaltrials.gov, MedDRA, SNOMED CT, DECIPHER, LOINC

For each phenotype, provide:
- **Phenotype type**: symptoms, clinical signs, physical manifestations, behavioral changes, or laboratory abnormalities
  > For symptoms/signs: HPO, OMIM, Orphanet, PubMed
  > For behavioral changes: HPO, DSM, RDoC (Research Domain Criteria), PubMed
  > For laboratory abnormalities: LOINC, SNOMED CT, LabTests Online, PubMed
- **Phenotype characteristics**:
  > **Search first:** OMIM, Orphanet, HPO, PubMed
  - Age of symptom onset (neonatal, childhood, adult-onset, late-onset)
  - Symptom severity (mild, moderate, severe, variable)
  - Symptom progression (stable, progressive, episodic, fluctuating)
  - Frequency among affected individuals (percentage or qualitative)
- **Quality of life impact**: Effects on daily functioning and well-being (per-phenotype when possible)
  > **Search first:** EQ-5D database, SF-36, WHO QOL databases, PubMed
- Suggest HPO (Human Phenotype Ontology) terms for each phenotype

### 4. Genetic/Molecular Information

- **Causal Genes**: Gene mutations or chromosomal abnormalities responsible for disease (gene symbols, OMIM IDs)
  > **Search first:** OMIM, ClinVar, HGMD, Ensembl, NCBI Gene
- **Pathogenic Variants**:
  - Affected genes (gene symbols, HGNC IDs)
    > **Search first:** OMIM, NCBI Gene, Ensembl, HGNC, UniProt, GeneCards
  - Variant classification (pathogenic, likely pathogenic, VUS per ACMG/AMP guidelines)
    > **Search first:** ClinVar, ClinGen, ACMG/AMP guidelines, VarSome
  - Variant type/class (missense, frameshift, nonsense, splice-site, structural)
  - Allele frequency in population databases
    > **Search first:** gnomAD, 1000 Genomes, ExAC, TOPMed, dbSNP
  - Somatic vs germline origin
    > **Search first:** COSMIC (somatic), ClinVar, ICGC, TCGA
  - Functional consequences (loss of function, gain of function, dominant negative)
- **Modifier Genes**: Genes that modify disease severity or expression
- **Epigenetic Information**: DNA methylation, histone modifications, chromatin changes affecting disease
  > **Search first:** ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth
- **Chromosomal Abnormalities**: Large-scale genetic changes (aneuploidy, translocations, inversions)
  > **Search first:** DECIPHER, ClinVar, ECARUCA, UCSC Genome Browser

### 5. Environmental Information

- **Environmental Factors**: Non-genetic contributing factors (toxins, radiation, pollution, occupational exposure)
  > **Search first:** CTD (Comparative Toxicogenomics Database), TOXNET, PubMed, EPA databases
- **Lifestyle Factors**: Behavioral factors (smoking, diet, exercise, alcohol consumption)
  > **Search first:** CDC databases, WHO, PubMed, NHANES
- **Infectious Agents**: If applicable, pathogens causing or triggering disease (bacteria, viruses, fungi, parasites)
  > **Search first:** NCBI Taxonomy, ViPR, BV-BRC, MicrobeDB, GIDEON

### 6. Mechanism / Pathophysiology

**Present this section as an ordered causal chain first, then the detail below.**
Open with a numbered sequence of mechanistic steps running from the initiating
lesion (mutation, exposure, infection) to the clinical manifestation, one step per
line, each naming what it causes next. State the causal verb explicitly ("leads
to", "results in") and say where a step is inferred rather than demonstrated.
Where the mechanism branches, show the branch. The categories below are a
checklist of what to cover within those steps, not the organizing structure —
a step may draw on several of them, and a category may contribute to several
steps.

- **Molecular Pathways**: Specific signaling cascades or biochemical pathways involved (Wnt, MAPK, mTOR, PI3K-AKT, etc.)
  > **Search first:** KEGG, Reactome, WikiPathways, PathBank, BioCyc
- **Cellular Processes**: Cell-level mechanisms (apoptosis, autophagy, cell cycle dysregulation, inflammation, etc.)
  > **Search first:** Gene Ontology (GO), Reactome, KEGG, PubMed
- **Protein Dysfunction**: How protein structure or function is altered (misfolding, aggregation, loss of function, gain of function)
  > **Search first:** UniProt, PDB (Protein Data Bank), InterPro, Pfam, AlphaFold
- **Metabolic Changes**: Alterations in metabolic processes (energy metabolism, lipid metabolism, amino acid metabolism)
  > **Search first:** KEGG, BioCyc, HMDB (Human Metabolome Database), BRENDA
- **Immune System Involvement**: Role of immune response (autoimmunity, immunodeficiency, chronic inflammation)
  > **Search first:** ImmPort, Immunome Database, IEDB, Gene Ontology
- **Tissue Damage Mechanisms**: How tissues/ are injured (oxidative stress, ischemia, fibrosis, necrosis)
  > **Search first:** PubMed, Gene Ontology, Reactome
- **Biochemical Abnormalities**: Specific molecular defects (enzyme deficiencies, receptor dysfunction, ion channel defects)
  > **Search first:** BRENDA, UniProt, KEGG, OMIM, PubMed
- **Epigenetic Changes**: DNA methylation, histone modifications affecting gene expression in disease
  > **Search first:** ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth
- **Molecular Profiling** (if available):
  - Transcriptomics/gene expression changes
    > **Search first:** GEO (Gene Expression Omnibus), ArrayExpress, GTEx, Human Cell Atlas, SRA
  - Proteomics findings
    > **Search first:** PRIDE, ProteomeXchange, Human Protein Atlas, STRING, BioGRID
  - Metabolomics signatures
    > **Search first:** MetaboLights, Metabolomics Workbench, HMDB, METLIN
  - Lipidomics alterations
    > **Search first:** LIPID MAPS, SwissLipids, LipidHome, Metabolomics Workbench
  - Genomic structural features
    > **Search first:** UCSC Genome Browser, Ensembl, NCBI, dbVar, DGV
- **Advanced Technologies** (if applicable):
  - Single-cell analysis findings (cell-type specific mechanisms, cellular heterogeneity)
    > **Search first:** Human Cell Atlas, Single Cell Portal, GEO, CELLxGENE
  - Spatial transcriptomics findings
    > **Search first:** GEO, Spatial Research, Vizgen, 10x Genomics data
  - Multi-omics integration results
    > **Search first:** TCGA, ICGC, cBioPortal, LinkedOmics, PubMed
  - Functional genomics screens (CRISPR, RNAi)
    > **Search first:** DepMap, GenomeRNAi, PubMed, BioGRID ORCS

For each mechanism, describe:
- The causal chain from initial trigger to clinical manifestation
- Which mechanisms are upstream vs downstream
- What cell types and biological processes are involved
- Suggest GO terms for biological processes and CL terms for cell types

### 7. Anatomical Structures Affected

- **Organ Level**:
  - Primary organs directly affected
  - Secondary organ involvement (complications, secondary effects)
  - Body systems involved (cardiovascular, nervous, digestive, respiratory, endocrine, etc.)
  > **Search first:** Uberon, FMA (Foundational Model of Anatomy), OMIM, HPO, ICD-11, MeSH, SNOMED CT
- **Tissue and Cell Level**:
  - Specific tissue types affected (epithelial, connective, muscle, nervous)
  - Specific cell populations targeted (with Cell Ontology terms)
  > **Search first:** Uberon, Human Protein Atlas, Cell Ontology, Human Cell Atlas, CellMarker, PanglaoDB
- **Subcellular Level**:
  - Cellular compartments involved (mitochondria, nucleus, ER, lysosomes) (with GO Cellular Component terms)
  > **Search first:** Gene Ontology (Cellular Component), UniProt, Human Protein Atlas
- **Localization**:
  - Specific anatomical sites (with UBERON terms)
    > **Search first:** FMA, Uberon, NeuroNames (for brain), SNOMED CT
  - Lateralization (unilateral, bilateral, asymmetric)
    > **Search first:** HPO, clinical literature, imaging databases

### 8. Temporal Development

- **Onset**:
  - Typical age of onset (congenital, pediatric, adult, geriatric)
  - Onset pattern (acute, subacute, chronic, insidious)
  > **Search first:** OMIM, Orphanet, HPO, PubMed
- **Progression**:
  - Disease stages (early, intermediate, advanced, end-stage)
    > **Search first:** Cancer Staging Manual (AJCC), WHO classifications, PubMed
  - Progression rate (rapid, slow, variable)
  - Disease course pattern (episodic, relapsing-remitting, progressive, stable)
  - Disease duration (self-limited, chronic lifelong)
  > **Search first:** Disease registries, longitudinal cohort databases, natural history studies, PubMed, Orphanet, OMIM
- **Patterns**:
  - Remission patterns (spontaneous, treatment-induced)
    > **Search first:** Clinical trial databases, disease registries, PubMed
  - Critical periods (time windows of vulnerability or opportunity for intervention)
    > **Search first:** PubMed, developmental biology databases, clinical guidelines

### 9. Inheritance and Population

- **Epidemiology**:
  - Prevalence (cases per 100,000 at given time)
  - Incidence (new cases per 100,000 per year)
  > **Search first:** Orphanet, CDC, WHO, GBD (Global Burden of Disease), national registries, SEER, disease registries
- **For Genetic Etiology**:
  - Inheritance pattern (AD, AR, X-linked, mitochondrial, multifactorial, polygenic)
    > **Search first:** OMIM, Orphanet, ClinVar, GTR (Genetic Testing Registry)
  - Penetrance (complete, incomplete, age-dependent)
    > **Search first:** ClinVar, OMIM, PubMed, ClinGen
  - Expressivity (variable, consistent)
    > **Search first:** OMIM, ClinVar, PubMed
  - Genetic anticipation (increasing severity in successive generations)
    > **Search first:** OMIM, PubMed (especially for repeat expansion disorders)
  - Germline mosaicism
    > **Search first:** ClinVar, OMIM, genetic counseling literature, PubMed
  - Founder effects (population-specific mutations)
    > **Search first:** gnomAD, population genetics databases, PubMed
  - Consanguinity role
    > **Search first:** OMIM, population studies, genetic counseling resources
  - Carrier frequency
    > **Search first:** gnomAD, carrier screening databases, GeneReviews, GTR
- **Population Demographics**:
  - Affected populations (ethnic or demographic groups with higher prevalence)
    > **Search first:** gnomAD, 1000 Genomes, PAGE Study, PubMed, population registries
  - Geographic distribution (endemic areas, regional variation)
    > **Search first:** WHO, CDC, GBD, Orphanet, geographic epidemiology databases
  - Geographic distribution of specific variants
  - Sex ratio (male:female)
    > **Search first:** Disease registries, OMIM, PubMed, epidemiological databases
  - Age distribution of affected individuals
    > **Search first:** CDC, disease registries, SEER, Orphanet

### 10. Diagnostics

- **Clinical Tests**:
  - Laboratory tests (blood, urine, tissue chemistry, specific enzyme assays)
    > **Search first:** LOINC, LabTests Online, PubMed
  - Biomarkers (proteins, metabolites, genetic markers, circulating biomarkers)
    > **Search first:** FDA Biomarker List, BEST (Biomarkers, EndpointS, and other Tools), PubMed
  - Imaging studies (X-ray, CT, MRI, PET, ultrasound)
    > **Search first:** RadLex, DICOM, Radiopaedia, imaging databases
  - Functional tests (pulmonary function, cardiac stress tests)
    > **Search first:** LOINC, clinical guidelines, PubMed
  - Electrophysiology (EEG, EMG, ECG, nerve conduction studies)
    > **Search first:** LOINC, clinical neurophysiology databases, PubMed
  - Biopsy findings (histopathology, immunohistochemistry)
    > **Search first:** SNOMED CT, College of American Pathologists resources, PubMed
  - Pathology findings (microscopic examination)
    > **Search first:** SNOMED CT, Digital Pathology databases, PubMed
- **Genetic Testing**:
  > **Search first:** GTR (Genetic Testing Registry), GeneReviews, ClinGen
  - Overview of recommended genetic testing approach
  - Whole genome sequencing (WGS) utility
    > **Search first:** GTR, ClinVar, GEL (Genomics England), gnomAD
  - Whole exome sequencing (WES) utility
    > **Search first:** GTR, ClinVar, OMIM, GeneMatcher
  - Gene panels (which panels, which genes)
    > **Search first:** GTR, ClinVar, laboratory-specific databases
  - Single gene testing
    > **Search first:** GTR, ClinVar, OMIM, GeneReviews
  - Chromosomal microarray (CMA)
    > **Search first:** DECIPHER, ClinVar, dbVar, ECARUCA
  - Karyotyping
    > **Search first:** Chromosome Abnormality Database, ClinVar, cytogenetics resources
  - FISH
    > **Search first:** ClinVar, cytogenetics databases, PubMed
  - Mitochondrial DNA testing
    > **Search first:** MITOMAP, MSeqDR, ClinVar, GTR
  - Repeat expansion testing
    > **Search first:** GTR, ClinVar, repeat expansion databases, PubMed
- **Omics-Based Diagnostics** (if applicable):
  - RNA sequencing / transcriptomics
    > **Search first:** GEO, ArrayExpress, GTEx, RNA-seq databases
  - Proteomics
    > **Search first:** PRIDE, ProteomeXchange, FDA Biomarker database
  - Metabolomics
    > **Search first:** MetaboLights, Metabolomics Workbench, HMDB
  - Epigenomics
    > **Search first:** GEO, ENCODE, Roadmap Epigenomics, MethBase
  - Liquid biopsy
    > **Search first:** COSMIC, ClinVar, liquid biopsy databases, PubMed
- **Clinical Criteria**:
  - Standardized diagnostic criteria (DSM, ICD, society guidelines)
    > **Search first:** DSM-5, ICD-11, clinical society guidelines, UpToDate
  - Differential diagnosis (other conditions to rule out, with distinguishing features)
    > **Search first:** DynaMed, UpToDate, clinical decision support systems
- **Screening**:
  - Screening methods for asymptomatic individuals (newborn screening, carrier screening, cascade screening)
    > **Search first:** ACMG recommendations, CDC newborn screening, GTR

### 11. Outcome/Prognosis

- **Survival and Mortality**:
  - Survival rate (5-year, 10-year, overall)
    > **Search first:** SEER, cancer registries, disease-specific registries, PubMed
  - Life expectancy (with and without treatment if applicable)
    > **Search first:** Orphanet, disease registries, actuarial databases, PubMed
  - Mortality rate
    > **Search first:** CDC, WHO, GBD, national mortality databases
  - Disease-specific mortality (deaths directly attributable to disease)
    > **Search first:** Disease registries, CDC Wonder, GBD, PubMed
- **Morbidity and Function**:
  - Morbidity (disease-related disability and health impacts)
    > **Search first:** GBD, WHO, disability databases, PubMed
  - Disability outcomes (long-term functional impairments)
    > **Search first:** ICF (International Classification of Functioning), disability registries
  - Quality of life measures (EQ-5D, SF-36, PROMIS, disease-specific tools)
    > **Search first:** EQ-5D database, SF-36, PROMIS, PubMed
- **Disease Course**:
  - Complications (secondary problems: infections, organ failure, etc.)
    > **Search first:** ICD codes, disease registries, clinical databases, PubMed
  - Recovery potential (likelihood and extent of recovery, with vs without treatment)
    > **Search first:** Natural history studies, rehabilitation databases, PubMed
- **Prediction**:
  - Prognostic factors (age, disease severity, biomarkers, treatment response)
    > **Search first:** Prognostic models databases, clinical calculators, PubMed
  - Prognostic biomarkers (molecular markers predicting disease course)
    > **Search first:** FDA Biomarker database, PubMed, cancer prognostic databases

### 12. Treatment

- **Pharmacotherapy**:
  - Pharmacological treatments (drug names, drug classes, mechanisms of action)
    > **Search first:** DrugBank, RxNorm, ATC classification, DailyMed, FDA databases
  - Pharmacogenomics (how genetic variants affect drug metabolism, efficacy, toxicity)
    > **Search first:** PharmGKB, CPIC (Clinical Pharmacogenetics), FDA Table of PGx Biomarkers
- **Advanced Therapeutics**:
  - Gene therapy (viral vectors, CRISPR, gene replacement, gene editing)
    > **Search first:** ClinicalTrials.gov, FDA gene therapy database, ASGCT resources
  - Cell therapy (stem cell transplant, CAR-T, cellular therapeutics)
    > **Search first:** ClinicalTrials.gov, FDA cell therapy database, FACT standards
  - RNA-based therapies (ASOs, siRNA, mRNA therapies)
    > **Search first:** ClinicalTrials.gov, FDA approvals, PubMed
  - Targeted therapies (treatments directed at specific molecular targets)
    > **Search first:** My Cancer Genome, OncoKB, ClinicalTrials.gov, FDA approvals
  - Immunotherapies (checkpoint inhibitors, monoclonal antibodies)
    > **Search first:** Cancer Immunotherapy Database, FDA approvals, ClinicalTrials.gov
- **Surgical and Interventional**:
  - Surgical interventions (types of surgery, timing, outcomes)
    > **Search first:** CPT codes, surgical registries, clinical guidelines, PubMed
- **Supportive and Rehabilitative**:
  - Supportive care (symptom management, pain control, nutrition)
    > **Search first:** Clinical guidelines, Cochrane Library, PubMed
  - Rehabilitation (physical therapy, occupational therapy, speech therapy)
    > **Search first:** Rehabilitation medicine databases, clinical guidelines, PubMed
- **Experimental**:
  - Experimental treatments in clinical trials (with NCT identifiers if available)
    > **Search first:** ClinicalTrials.gov, EU Clinical Trials Register, WHO ICTRP
- **Treatment Outcomes**:
  - Treatment response rates
    > **Search first:** Clinical trial databases, FDA reviews, systematic reviews, PubMed
  - Side effects and adverse events
    > **Search first:** FDA Adverse Event Reporting System (FAERS), MedWatch, PubMed
- **Treatment Strategy**:
  - Treatment algorithms (clinical pathways, decision trees)
    > **Search first:** Clinical practice guidelines, NCCN Guidelines, UpToDate
  - Combination therapies
    > **Search first:** ClinicalTrials.gov, treatment guidelines, PubMed
  - Personalized medicine approaches (genotype-guided treatment)
    > **Search first:** My Cancer Genome, CIViC, PharmGKB, precision medicine databases

For each treatment, suggest NCIT (NCI Thesaurus) clinical-intervention terms where applicable.

### 13. Prevention

- **Prevention Levels**:
  - Primary prevention (preventing disease occurrence: vaccination, risk factor modification)
    > **Search first:** CDC, WHO, USPSTF recommendations, Cochrane Library
  - Secondary prevention (early detection and treatment: screening programs, early intervention)
    > **Search first:** USPSTF, CDC screening guidelines, WHO
  - Tertiary prevention (preventing complications in those with disease)
    > **Search first:** Clinical guidelines, disease management protocols, PubMed
- **Immunization**: Vaccine strategies (if applicable)
  > **Search first:** CDC vaccine schedules, WHO immunization, FDA vaccine database
- **Screening and Early Detection**:
  - Screening programs (population-based: newborn screening, cancer screening)
    > **Search first:** CDC screening programs, USPSTF, cancer screening databases
  - Genetic screening (carrier screening, preimplantation genetic diagnosis, prenatal testing)
    > **Search first:** ACMG recommendations, ACOG guidelines, GTR
  - Risk stratification (identifying high-risk individuals for targeted prevention)
    > **Search first:** Risk prediction models, clinical calculators, PubMed
- **Behavioral Interventions**: Lifestyle modifications to reduce risk
  > **Search first:** CDC, WHO, behavioral intervention databases, Cochrane Library
- **Counseling**: Genetic counseling (risk assessment, family planning guidance)
  > **Search first:** NSGC resources, ACMG guidelines, GeneReviews
- **Public Health**:
  - Public health interventions (sanitation, vector control, health education)
    > **Search first:** CDC, WHO, public health databases, PubMed
  - Environmental interventions (reducing environmental risk factors)
    > **Search first:** EPA databases, WHO environmental health, PubMed
- **Prophylaxis**: Preventive medications or procedures
  > **Search first:** Clinical guidelines, FDA approvals, PubMed

### 14. Other Species / Natural Disease

- **Taxonomy**: Species affected (with NCBI Taxon identifiers)
  > **Search first:** NCBI Taxonomy
- **Breed**: Specific breeds affected (with VBO identifiers if applicable)
  > **Search first:** VBO (Vertebrate Breed Ontology)
- **Gene**: Orthologous genes in other species (with NCBI Gene IDs)
  > **Search first:** NCBI Gene
- **Natural Disease**:
  - Naturally occurring disease in other species (companion animals, wildlife)
    > **Search first:** OMIA (Online Mendelian Inheritance in Animals), VetCompass, PubMed
  - Veterinary relevance and importance in animal health
    > **Search first:** OMIA, veterinary databases, PubMed
- **Comparative Biology**:
  - Comparative pathology (similarities and differences across species)
    > **Search first:** OMIA, comparative pathology databases, PubMed
  - Evolutionary conservation of disease mechanisms
    > **Search first:** HomoloGene, OrthoMCL, Alliance of Genome Resources
- **Transmission** (if applicable):
  - Zoonotic potential
    > **Search first:** CDC zoonotic diseases, WHO zoonoses, GIDEON
  - Cross-species susceptibility
    > **Search first:** NCBI Taxonomy, veterinary databases, PubMed

### 15. Model Organisms

- **Model Types**:
  - Model organism type (mammalian, invertebrate, cellular, in vitro)
    > **Search first:** Alliance of Genome Resources, model organism databases
  - Specific model systems (mouse, rat, zebrafish, Drosophila, C. elegans, yeast, cell lines, organoids, iPSCs)
    > **Search first:** MGI, RGD, ZFIN, FlyBase, WormBase, SGD, ATCC, Cellosaurus
  - Induced models (drug treatment, surgical intervention, environmental manipulation)
    > **Search first:** MGI, model organism databases, PubMed
- **Genetic Models**:
  - Types available (knockout, knock-in, transgenic, conditional, humanized)
    > **Search first:** MGI, IMPC, KOMP, EuMMCR, IMSR
- **Model Characteristics**:
  - Phenotype recapitulation (how well model reproduces human disease features)
    > **Search first:** Model organism databases, comparative studies, PubMed
  - Model limitations (aspects of human disease not captured)
    > **Search first:** Model organism databases, PubMed, review articles
- **Applications**:
  - Research applications (what aspects of disease can be studied)
    > **Search first:** Model organism databases, PubMed
- **Resources**:
  - Model databases
    > **Search first:** MGI, RGD, ZFIN, FlyBase, WormBase, IMSR, EMMA, MMRRC

---

## Citation Requirements

- Cite primary literature (PMID preferred) for all mechanistic and clinical claims
- Prioritize recent reviews and landmark papers
- Include direct quotes from abstracts where possible to support key statements
- Distinguish evidence source types: human clinical, model organism, in vitro, computational

## Output Format

Structure your response as a comprehensive narrative organized by the sections above.
For each section, provide:
- Factual content with specific details (numbers, percentages, gene names, variant nomenclature)
- Ontology term suggestions (HPO, GO, CL, UBERON, CHEBI, NCIT, MONDO) where applicable
- Evidence citations with PMIDs
- Direct quotes from abstracts to support key claims
- Clear indication when information is not available or not applicable for this disease

This report will be used to populate a disease knowledge base entry with:
- Pathophysiology descriptions with causal chains
- Gene/protein annotations (HGNC, GO terms)
- Phenotype associations (HP terms) with frequencies
- Cell type involvement (CL terms)
- Anatomical locations (UBERON terms)
- Chemical entities (CHEBI terms)
- Treatment annotations (NCIT terms)
- Evidence items with PMIDs and exact abstract quotes
- Epidemiology, prognosis, diagnostic, and prevention information
- Animal model descriptions with phenotype recapitulation details


## Output

# Brachyolmia–Amelogenesis Imperfecta Syndrome (Dental Anomalies and Short Stature Syndrome, DASS): A Comprehensive Disease Report

**Disease:** Brachyolmia–Amelogenesis Imperfecta Syndrome
**Primary synonym:** Dental Anomalies and Short Stature syndrome (DASS)
**Causal gene:** *LTBP3* (Latent TGF-β Binding Protein 3)
**Category:** Mendelian, autosomal recessive
**Key identifiers:** OMIM 601216 (disease phenotype); OMIM 602090 (*LTBP3* gene); HGNC:6716; NCBI Gene 4054; UniProt Q9NS15

---

## Summary

Brachyolmia–Amelogenesis Imperfecta Syndrome — now most often called **Dental Anomalies and Short Stature syndrome (DASS; OMIM 601216)** — is an **ultra-rare autosomal recessive Mendelian disorder** caused by **biallelic loss-of-function (hypomorphic) variants in *LTBP3***, the gene encoding Latent Transforming Growth Factor-β Binding Protein 3. First delineated by Verloes and colleagues in 1996 as a new form of skeletal dysplasia combining amelogenesis imperfecta with platyspondyly, the molecular cause was established in 2015 when whole-exome sequencing of four families identified recessive deletion, nonsense, and splice-site *LTBP3* mutations. The disorder is defined by a characteristic clinical triad: **significant short stature with brachyolmia** (a mild, generalized platyspondylic skeletal dysplasia), **hypoplastic amelogenesis imperfecta with near-absent enamel**, and a spectrum of **orodental anomalies** (oligodontia/hypodontia, delayed or failed eruption, taurodontism, abnormal dentin, underdeveloped maxilla).

Mechanistically, LTBP3 is a secreted extracellular-matrix protein that anchors the large latent TGF-β complex (TGF-β + LAP propeptide + LTBP) to fibrillin-1 microfibrils, thereby governing the secretion, matrix localization, and bioavailability of TGF-β. Biallelic LTBP3 loss disrupts assembly of the TGF-β–LAP–LTBP3 latent complex, perturbing TGF-β secretion/activation and downstream SMAD2/3 and ERK1/2 signaling in a **context- and dose-dependent** manner, producing dental, skeletal, and cardiovascular consequences. The *Ltbp3*-null mouse faithfully recapitulates the human phenotype (reduced body size, craniofacial/skull-base synchondrosis abnormalities, high bone mass with low turnover, and thin-to-absent enamel), providing strong causal validation.

Clinically, DASS is a chronic, lifelong, largely **non–life-threatening** condition dominated by dental and skeletal morbidity, but it carries important **cardiovascular risk** — **thoracic aortic aneurysm and dissection (TAAD)** has been documented in both biallelic and heterozygous *LTBP3* carriers. *LTBP3* also exhibits a striking **allelic series**: monoallelic missense or de novo variants instead cause dominant **acromicric dysplasia** or lethal **geleophysic dysplasia** (respiratory failure in early childhood), placing the gene within the acromelic/microfibrillar-network disorder family. There is **no disease-modifying therapy**; management is supportive and multidisciplinary (restorative dentistry with ceramic crowns as first-line, orthodontic/orthognathic/prosthodontic rehabilitation, growth monitoring, and echocardiographic aortic surveillance), while prevention is reproductive (genetic counseling, carrier/cascade testing, prenatal and preimplantation genetic diagnosis), particularly relevant in the consanguineous and founder populations in which the disorder is enriched.

---

## 1. Disease Information

**Overview.** DASS is a rare autosomal recessive syndrome combining a mild spondylar skeletal dysplasia (brachyolmia) with a severe enamel defect (hypoplastic amelogenesis imperfecta) and short stature. The condition was first characterized clinically by Verloes et al. (1996) in two children of consanguineous parents and molecularly resolved to *LTBP3* by Huckert et al. (2015). It is described as being "characterized by significant short stature with brachyolmia and hypoplastic amelogenesis imperfecta (AI) with almost absent enamel" ([PMID: 25669657](https://pubmed.ncbi.nlm.nih.gov/25669657/)).

**Key identifiers.**

| Resource | Identifier |
|---|---|
| OMIM (disease) | 601216 |
| OMIM (gene, *LTBP3*) | 602090 |
| HGNC | HGNC:6716 |
| NCBI Gene | 4054 |
| UniProt | Q9NS15 |
| MONDO | Brachyolmia–amelogenesis imperfecta syndrome / DASS (cross-referenced to OMIM 601216) |

**Synonyms and alternative names:**
- Dental Anomalies and Short Stature syndrome (DASS) — the current preferred designation
- Brachyolmia–amelogenesis imperfecta syndrome
- Brachyolmia with amelogenesis imperfecta
- Amelogenesis imperfecta and platyspondyly (as originally described)
- LTBP3-related skeletal dysplasia

The synonym "DASS" and OMIM number are established explicitly: "Mutations in LTBP3 are associated with Dental Anomalies and Short Stature syndrome (DASS; MIM 601216)" ([PMID: 35352826](https://pubmed.ncbi.nlm.nih.gov/35352826/)).

**Source of information.** The evidence base is derived from **aggregated disease-level resources** — case reports and small family series (whole-exome sequencing studies of consanguineous families), a mouse knockout model, and biochemical studies of TGF-β latent complex biology — rather than from large individual-patient EHR datasets. As of 2020 only ~20 individuals from 9 families had been reported.

---

## 2. Etiology

**Disease causal factors.** DASS is a **monogenic (Mendelian) genetic disorder**. The primary and sole established cause is **biallelic loss-of-function / hypomorphic variation in *LTBP3***. There is no environmental, infectious, or acquired etiology. Huckert et al. identified "recessive hypomorphic mutations including deletion, nonsense and splice mutations, in the LTBP3 gene, which is involved in the TGF-beta signaling pathway" ([PMID: 25669657](https://pubmed.ncbi.nlm.nih.gov/25669657/)).

**Genetic risk factors.**
- **Causal variants:** Biallelic (homozygous or compound heterozygous) loss-of-function *LTBP3* variants — including deletions, nonsense, frameshift, and canonical splice-site mutations.
- **Consanguinity:** A major risk factor. Most reported families are consanguineous, increasing the probability of homozygosity for a rare recessive allele ([PMID: 8721563](https://pubmed.ncbi.nlm.nih.gov/8721563/)).
- **Founder alleles:** Population-specific founder variants exist — e.g., a Druze Arab founder variant (c.1346-1G>A) localized by homozygosity mapping to chromosome 11p11.2–q13.3 ([PMID: 37394436](https://pubmed.ncbi.nlm.nih.gov/37394436/)).

**Environmental risk factors.** None identified. As a fully penetrant recessive Mendelian disorder, no environmental, occupational, or lifestyle exposures are known to cause or trigger DASS.

**Protective factors.** No genetic modifier alleles or environmental protective factors are documented (see Modifier Genes below).

**Gene–environment interactions.** None documented. Given the monogenic recessive architecture, disease occurrence is determined by genotype; however, mechanical/environmental factors may plausibly modulate the *severity* of downstream consequences (e.g., spinal deformity influencing aortic mechanics — see Prognosis), though this is inferred rather than demonstrated in patients.

---

## 3. Phenotypes

The phenotype is remarkably consistent across families and populations. Below, phenotypes are grouped with suggested HPO terms, characteristics, and frequency.

| Phenotype | Type | HPO term (suggested) | Onset | Severity | Frequency |
|---|---|---|---|---|---|
| Hypoplastic amelogenesis imperfecta / near-absent enamel | Physical/dental sign | HP:0000705 (Amelogenesis imperfecta) | Congenital (both dentitions) | Severe | Near-universal (defining) |
| Short stature | Physical sign | HP:0004322 (Short stature) | Postnatal/childhood | Moderate–severe | Near-universal (defining) |
| Brachyolmia / platyspondyly | Skeletal/radiographic | HP:0000926 (Platyspondyly) | Childhood | Mild–moderate | Near-universal (defining) |
| Oligodontia / hypodontia | Dental | HP:0000670 / HP:0000668 | Congenital | Variable | Frequent |
| Delayed/failed tooth eruption | Dental | HP:0000684 (Delayed eruption of teeth) | Childhood | Variable | Frequent |
| Taurodontism | Dental | HP:0000679 (Taurodontism) | Congenital | Mild | Reported |
| Abnormal dentin | Dental | HP:0011063 (Abnormal dentin morphology) | Congenital | Variable | Reported |
| Underdeveloped/hypoplastic maxilla | Craniofacial | HP:0000327 (Hypoplasia of the maxilla) | Childhood | Variable | Frequent |
| Broad femoral necks | Skeletal | HP:0012865 (Broad femoral neck) | Childhood | Mild | Reported |
| Vertebral scalloping / rectangular vertebrae | Radiographic | Posterior vertebral scalloping | Childhood | Mild | Reported |
| Thoracic aortic aneurysm/dissection | Cardiovascular | HP:0004942 / HP:0002647 | Adult (variable) | Severe (serious complication) | Reported subset |
| Nephrocalcinosis | Laboratory/imaging | HP:0000121 (Nephrocalcinosis) | Variable | Variable | Occasional (Moroccan families) |
| Malocclusion / open bite | Dental | HP:0000689 (Dental malocclusion) | Childhood | Variable | Frequent |

The original description captured the skeletal-dental core: "amelogenesis imperfecta (absence of the enamel cap) associated with brachyolmia-like anomalies: platyspondyly with short pedicles, narrow intervertebral and interpedicular distances, rectangular-shaped vertebrae with posterior scalloping and herniation of the nuclei, and broad femoral necks" ([PMID: 8721563](https://pubmed.ncbi.nlm.nih.gov/8721563/)). Later series expanded the orodental spectrum and added aortic involvement: "hypoplastic type amelogenesis imperfecta, hypodontia, underdeveloped maxilla, short stature, brachyolmia, aneurysm and dissection of the thoracic aorta" ([PMID: 35352826](https://pubmed.ncbi.nlm.nih.gov/35352826/)).

**Quality-of-life impact.** The amelogenesis imperfecta component drives substantial functional and psychosocial burden. In a cohort of 68 children/adolescents (7–19 y), "Children under 13 years were more frequently reported functional difficulties, such as pain and eating challenges, while adolescents (≥ 13 years) more often expressed psychosocial concerns including bullying and low self-confidence" ([PMID: 42113459](https://pubmed.ncbi.nlm.nih.gov/42113459/)). Interview studies find "the impact of AI on quality of life is more severe than previously appreciated" ([PMID: 38909645](https://pubmed.ncbi.nlm.nih.gov/38909645/)). Short stature and skeletal features add further functional and psychosocial dimensions.

---

## 4. Genetic / Molecular Information

**Causal gene.** ***LTBP3*** (Latent TGF-β Binding Protein 3), chromosome 11q13.1; gene OMIM 602090; HGNC:6716; NCBI Gene 4054; protein UniProt Q9NS15.

**Pathogenic variants.** DASS is caused by **biallelic loss-of-function/hypomorphic** variants. Reported variant classes include:

| Variant (example) | Type | Predicted effect | Population/Source |
|---|---|---|---|
| Deletion, nonsense, splice mutations | LOF | Loss of function | Four families ([PMID: 25669657](https://pubmed.ncbi.nlm.nih.gov/25669657/)) |
| c.2495delT (p.Phe832SerfsTer36) | Frameshift | LOF | Moroccan family 1 ([PMID: 35998423](https://pubmed.ncbi.nlm.nih.gov/35998423/)) |
| c.3716G>A (p.Cys1239Tyr) | Missense (destabilizing) | Structural destabilization | Moroccan family 2 ([PMID: 35998423](https://pubmed.ncbi.nlm.nih.gov/35998423/)) |
| c.625dup (p.Leu209fs) + c.1965del (p.Arg656fs) | Compound het frameshift | LOF | TAAD patient with short stature/dental problems ([PMID: 34906192](https://pubmed.ncbi.nlm.nih.gov/34906192/)) |
| c.1346-1G>A | Splice acceptor | LOF | Druze Arab founder ([PMID: 37394436](https://pubmed.ncbi.nlm.nih.gov/37394436/)) |

**ACMG/AMP classification.** Reported causal variants are generally **pathogenic/likely pathogenic** (null variants meeting PVS1-type criteria, segregating in consanguineous families with a specific, well-established phenotype). The missense p.Cys1239Tyr variant was supported functionally by molecular modeling that "disclosed a possible destabilization of the wild-type structure" ([PMID: 35998423](https://pubmed.ncbi.nlm.nih.gov/35998423/)).

**Allele frequency.** Causal alleles are ultra-rare/private; population-database (gnomAD) frequencies for reported pathogenic variants are extremely low, consistent with a recessive ultra-rare disorder enriched by consanguinity and founder effects.

**Somatic vs germline.** All disease-causing variants are **germline**; no somatic contribution is relevant.

**Functional consequences.** **Loss of function** — variants abrogate LTBP3's ability to form the TGF-β–LAP–LTBP3 latent complex and localize latent TGF-β to fibrillin microfibrils: "failure of TGFβ-LAP-LTBP3 complex formation, and subsequent disruption of TGFβ secretion and activation" ([PMID: 35352826](https://pubmed.ncbi.nlm.nih.gov/35352826/)).

**Genotype–phenotype correlation (allelic series).** A key principle: "biallelic loss-of-function mutations cause DASS, monoallelic missense" variants cause acromicric dysplasia ([PMID: 30887145](https://pubmed.ncbi.nlm.nih.gov/30887145/)). Dominant missense (c.2087C>G, p.Ser696Cys) causes acromicric dysplasia, and de novo heterozygous variants (splice c.1846+5G>A; stop-loss p.1304*ext*12) cause lethal geleophysic dysplasia ([PMID: 27068007](https://pubmed.ncbi.nlm.nih.gov/27068007/)).

**Modifier genes.** No specific modifier genes are identified for DASS. Given LTBP3's function within the fibrillin-microfibril/TGF-β network, genes encoding partner proteins (FBN1, LTBP2, ADAMTS10/17, ADAMTSL2) are biologically plausible modifiers but not demonstrated.

**Epigenetic information.** No DNA-methylation, histone-modification, or chromatin-based mechanisms have been reported for DASS. Not applicable based on current evidence.

**Chromosomal abnormalities.** DASS is a single-gene disorder; no aneuploidy, translocation, or large structural rearrangement is characteristic. Homozygosity mapping (not a structural abnormality) identified the 11p11.2–q13.3 founder region in Druze Arab patients ([PMID: 37394436](https://pubmed.ncbi.nlm.nih.gov/37394436/)).

---

## 5. Environmental Information

**Environmental factors, lifestyle factors, and infectious agents:** **Not applicable.** DASS is a purely genetic, autosomal recessive Mendelian disorder. No toxins, radiation, pollution, occupational exposures, dietary/behavioral factors, or infectious agents contribute to its causation. Consanguinity (a demographic/social factor) increases the probability of an affected offspring but is not an environmental cause of the molecular lesion itself.

---

## 6. Mechanism / Pathophysiology

### Ordered causal chain (initiating lesion → clinical manifestation)

1. **Biallelic loss-of-function *LTBP3* variants** (deletion/nonsense/frameshift/splice) **lead to** absent or non-functional LTBP-3 protein. *(Demonstrated.)*
2. Loss of functional LTBP-3 **results in** failure to assemble the large latent complex (TGF-β + LAP + LTBP-3), i.e., "failure of TGFβ-LAP-LTBP3 complex formation" ([PMID: 35352826](https://pubmed.ncbi.nlm.nih.gov/35352826/)). *(Demonstrated biochemically.)*
3. Failed complex assembly **disrupts** TGF-β secretion and its targeting to fibrillin-1 microfibrils in the ECM (matrices lacking fibrillin-1 also lack LTBP-3). *(Demonstrated in vitro.)*
4. Mislocalized/reduced latent TGF-β **alters** the local bioavailability and activation of TGF-β, **dysregulating** downstream **SMAD2/3** and **ERK1/2** signaling in a **context- and dose-dependent** manner ([PMID: 26494287](https://pubmed.ncbi.nlm.nih.gov/26494287/)). *(Demonstrated in mouse aorta; inferred for other tissues.)*
5. **Branch A — Teeth:** In differentiated ameloblasts (which express *Ltbp3*) and odontoblasts, disrupted TGF-β signaling **impairs** enamel matrix deposition and mineralization, **producing** hypoplastic amelogenesis imperfecta with near-absent enamel and abnormal dentin. *(Demonstrated: mouse enamel phenotype + ameloblast/odontoblast expression.)*
6. **Branch B — Skeleton:** Reduced TGF-β in bone and cartilage **compromises** osteoclast function and **decreases** bone turnover, **causing** premature ossification of skull-base synchondroses, altered vertebral/long-bone growth, short stature, brachyolmia, and (in mouse) an osteopetrosis-like high-bone-mass state ([PMID: 15878314](https://pubmed.ncbi.nlm.nih.gov/15878314/)). *(Demonstrated in mouse; inferred in humans.)*
7. **Branch C — Cardiovascular:** Altered TGF-β regulation and ECM/microfibril integrity **predispose** the thoracic aortic wall to medial elastic-fiber disruption, **leading to** aneurysm and dissection (TAAD) ([PMID: 34906192](https://pubmed.ncbi.nlm.nih.gov/34906192/)). *(Demonstrated in patients and mouse models; context-dependent.)*
8. These branches **manifest clinically** as the DASS triad plus its cardiovascular complications.

### Mechanistic detail

```
 LTBP3 biallelic LOF
        │
        ▼
 No functional LTBP-3 protein
        │
        ▼
 Failed TGF-β–LAP–LTBP3 latent complex assembly
        │
        ▼
 Disrupted TGF-β secretion + loss of targeting to
 fibrillin-1 microfibrils (ECM mislocalization)
        │
        ▼
 Altered TGF-β bioavailability/activation
 → dysregulated SMAD2/3 + ERK1/2 signaling
        │
   ┌────┼───────────────┬────────────────────┐
   ▼    ▼               ▼                    ▼
 TEETH  SKELETON     CRANIOFACIAL         AORTA
 (ameloblast/  (osteoclast   (skull-base    (medial elastic
 odontoblast   dysfunction,  synchondrosis   fiber disruption)
 dysfunction)  low turnover) premature       │
   │            │           ossification)    ▼
   ▼            ▼            ▼               TAAD
 Amelogenesis Short stature/ Underdeveloped
 imperfecta   brachyolmia    maxilla
```

- **Molecular pathways:** TGF-β signaling (canonical SMAD2/3 and non-canonical ERK1/2/MAPK). "TGFβ is secreted from cells as a latent complex consisting of TGFβ, the TGFβ propeptide, and a molecule of latent TGFβ binding protein (LTBP)" ([PMID: 26494287](https://pubmed.ncbi.nlm.nih.gov/26494287/)).
- **Cellular processes:** Ameloblast enamel-matrix secretion, odontoblast dentinogenesis, osteoclast-mediated bone resorption/turnover, chondrocyte/synchondrosis ossification, aortic smooth-muscle/ECM homeostasis.
- **Protein dysfunction:** Loss of function of a secreted ECM scaffolding protein; missense variants (e.g., p.Cys1239Tyr; EGF-like calcium-binding domain variants) can act via structural destabilization or dominant-negative effects in the allelic-series disorders.
- **Tissue damage mechanisms:** Aortic medial "disruption and fragmentation of medial elastic fibers" ([PMID: 26494287](https://pubmed.ncbi.nlm.nih.gov/26494287/)); defective enamel biomineralization; abnormal endochondral/synchondrosis ossification.
- **Biochemical abnormality:** Failure of latent TGF-β complex assembly and reduced ECM-localized TGF-β.

**Suggested GO terms:** transforming growth factor beta receptor signaling pathway (GO:0007179); regulation of transforming growth factor beta production (GO:0071634); extracellular matrix organization (GO:0030198); biomineral tissue development (GO:0031214); bone resorption (GO:0045453); ossification (GO:0001503).
**Suggested CL terms:** ameloblast (CL:0000059); odontoblast (CL:0000060); osteoclast (CL:0000092); osteoblast (CL:0000062); chondrocyte (CL:0000138); vascular smooth muscle cell (CL:0000359).

---

## 7. Anatomical Structures Affected

**Organ level (primary):** Teeth (enamel and dentin), axial skeleton (vertebrae/spine), long bones, craniofacial skeleton (skull-base synchondroses, maxilla).
**Secondary/complication organs:** Thoracic aorta and cardiovascular structures (interatrial septum, cardiac valves); occasionally kidneys (nephrocalcinosis in some Moroccan families, [PMID: 35998423](https://pubmed.ncbi.nlm.nih.gov/35998423/)).
**Body systems:** Skeletal, dental/oral, cardiovascular; (renal, occasionally).

**Tissue and cell level:** Mineralized dental tissues (enamel produced by ameloblasts; dentin by odontoblasts) — "Differentiated ameloblasts synthesizing enamel matrix proteins and odontoblasts expressed the gene" ([PMID: 25669657](https://pubmed.ncbi.nlm.nih.gov/25669657/)); cartilage/bone (chondrocytes, osteoblasts, osteoclasts); aortic media (elastic fibers, vascular smooth muscle cells).

**Subcellular level:** LTBP-3 is a **secreted extracellular matrix protein** localized to **fibrillin-1 microfibrils** (extracellular region; GO:0031012 extracellular matrix). It transits the secretory pathway (ER/Golgi) prior to secretion.

**Localization (UBERON):** tooth enamel (UBERON:0001752); dentine (UBERON:0001751); vertebral column (UBERON:0001130); femur/femoral neck (UBERON:0000981); maxilla (UBERON:0002397); cranial base region (UBERON:0011156); thoracic aorta (UBERON:0001515).
**Lateralization:** Bilateral/generalized (systemic skeletal and dental involvement); aortic disease affects the midline thoracic aorta.

---

## 8. Temporal Development

**Onset:** **Congenital to early childhood.** Enamel defects affect both primary and permanent dentitions (congenital), and short stature/brachyolmia become apparent in the postnatal/childhood growth period. Onset pattern is **chronic and insidious** (a developmental dysplasia), not acute.

**Progression:** DASS is a **chronic, lifelong, essentially non-progressive skeletal dysplasia**. The skeletal and dental features are developmentally determined and stable rather than degenerative. Dental morbidity (enamel breakdown, caries susceptibility, tooth loss) can accumulate over time if untreated. The **cardiovascular complication (TAAD) is a later, potentially progressive risk** that can present in adulthood and represents the most serious temporal dimension.

**Disease course pattern:** Stable/chronic for skeletal-dental features; the aortic component is progressive/episodic (aneurysm growth punctuated by acute dissection risk). Disease duration is lifelong.

**Patterns / critical periods:**
- **Odontogenesis (fetal–childhood):** the critical window during which enamel/dentin defects are established — no post-hoc biological remediation of enamel is possible.
- **Growth period (childhood–adolescence):** window for growth monitoring and orthodontic/orthognathic planning.
- **Adulthood:** window for aortic surveillance and timely intervention.
No spontaneous remission occurs; "remission" applies only to symptom control via restorative treatment.

---

## 9. Inheritance and Population

**Epidemiology.** DASS is **ultra-rare**: "Only 20 individuals from nine families have been previously reported, with a consistent phenotype of short stature, brachyolmia, and amelogenesis imperfecta" ([PMID: 32432408](https://pubmed.ncbi.nlm.nih.gov/32432408/)). Additional families have since been reported across French, Turkish, Moroccan, Indian, Druze Arab, and East Asian populations. Precise prevalence/incidence figures are not established given the rarity; the disorder falls well below the 1/1,000,000 range typical of ultra-rare recessive dysplasias.

**Inheritance pattern:** **Autosomal recessive** — "Inheritance appears to be autosomal recessive" ([PMID: 8721563](https://pubmed.ncbi.nlm.nih.gov/8721563/)); caused by biallelic hypomorphic/LOF variants.

**Penetrance and expressivity:** The core triad appears **highly/completely penetrant** in individuals with biallelic LOF variants. **Expressivity is variable**, particularly for severity of dental involvement, nephrocalcinosis (some families), and cardiovascular risk. Reports note "difference in severity" even within a family ([PMID: 35998423](https://pubmed.ncbi.nlm.nih.gov/35998423/)).

**Genetic anticipation:** Not applicable (not a repeat-expansion disorder).

**Germline mosaicism:** Not specifically reported.

**Founder effects:** Documented — the Druze Arab founder variant c.1346-1G>A, with homozygosity mapping to chromosome 11p11.2–q13.3 ([PMID: 37394436](https://pubmed.ncbi.nlm.nih.gov/37394436/)).

**Consanguinity:** A major contributor; most families are consanguineous ([PMID: 8721563](https://pubmed.ncbi.nlm.nih.gov/8721563/)).

**Carrier frequency:** Not established at the population level; expected to be very low outside founder groups.

**Population demographics / geographic distribution:** Reported worldwide but enriched in populations with high consanguinity rates and in specific founder communities. **Sex ratio** is expected to be **1:1** (autosomal recessive; no sex bias reported). **Age distribution:** affected individuals identified from childhood (dental/growth features) through adulthood (cardiovascular presentation).

---

## 10. Diagnostics

**Clinical recognition.** Diagnosis begins with recognition of the characteristic triad — **short stature + brachyolmia (platyspondyly) + hypoplastic amelogenesis imperfecta** — on combined clinical, dental, and radiographic examination.

**Imaging:** Skeletal radiographs of the **spine and pelvis** reveal platyspondyly, short pedicles, narrow intervertebral/interpedicular distances, rectangular vertebrae with posterior scalloping, and broad femoral necks ([PMID: 8721563](https://pubmed.ncbi.nlm.nih.gov/8721563/)). Dental radiographs demonstrate near-absent enamel, taurodontism, oligodontia/hypodontia, and unerupted teeth. **Echocardiography** (and cross-sectional aortic imaging) is indicated to evaluate for thoracic aortic aneurysm and cardiac structural anomalies.

**Genetic testing (definitive).** Molecular confirmation is by identifying **biallelic *LTBP3* variants**. Recommended approaches:
- **Whole-exome sequencing (WES):** the primary discovery and diagnostic tool in reported families ([PMID: 25669657](https://pubmed.ncbi.nlm.nih.gov/25669657/), [PMID: 35998423](https://pubmed.ncbi.nlm.nih.gov/35998423/)).
- **Targeted single-gene *LTBP3* sequencing** or **gene panels** (skeletal dysplasia / amelogenesis imperfecta panels).
- **Whole-genome sequencing (WGS)** where WES is uninformative.
- **Homozygosity mapping / chromosomal microarray (SNP array):** especially valuable in consanguineous families to identify runs of homozygosity harboring *LTBP3* — "One homozygote region in chromosome 11 (11p11.2-11q13.3) was found in all patients" ([PMID: 37394436](https://pubmed.ncbi.nlm.nih.gov/37394436/)).
- Karyotyping, FISH, mitochondrial DNA testing, and repeat-expansion testing are **not applicable**.

**Omics-based diagnostics:** Not routinely used; research-level functional studies (e.g., molecular modeling of missense variants, TGF-β signaling assays) support variant classification.

**Clinical criteria / differential diagnosis.** No formal consensus criteria exist; diagnosis is triad-based plus molecular confirmation. Key **differential diagnoses**:

| Condition | Gene | Distinguishing feature |
|---|---|---|
| Brachyolmia, dominant type | *TRPV4* | Dominant; no amelogenesis imperfecta |
| Brachyolmia, recessive (Hobaek/Maroteaux) / PAPSS2 type | *PAPSS2* | Recessive brachyolmia without the AI/enamel defect |
| Acromicric dysplasia | *LTBP3* (monoallelic missense), *FBN1*, *ADAMTSL2* | Dominant; short stature with stubby hands, no AI |
| Geleophysic dysplasia | *LTBP3* (de novo), *FBN1*, *ADAMTSL2*, *ADAMTS10/17* | Lethal cardiorespiratory disease; "happy face"; no AI triad |
| Isolated amelogenesis imperfecta | *AMELX*, *ENAM*, *MMP20*, *FAM83H*, etc. | Enamel defect without brachyolmia/short stature |

Brachyolmia's genetic heterogeneity is well established: "there are 3 and possibly 4 different types of brachyolmia" ([PMID: 2669482](https://pubmed.ncbi.nlm.nih.gov/2669482/)).

**Screening.** Cascade carrier testing within families and founder-population carrier screening are the principal screening modalities (see Prevention).

---

## 11. Outcome / Prognosis

**Overall prognosis:** DASS is a **chronic, lifelong, generally non–life-threatening** condition. The dominant burden is **dental** (pain, hypersensitivity, tooth breakdown/loss, malocclusion, aesthetic/psychosocial impact) and **short stature/skeletal** — none of which are inherently life-limiting.

**Serious/lethal risks:**
- **Thoracic aortic aneurysm and dissection (TAAD):** the principal life-threatening complication, reported in biallelic and heterozygous *LTBP3* carriers — "The identification of LTBP3 mutations in TAAD patients in our study provided more clinical evidence to support its association with TAAD" ([PMID: 34906192](https://pubmed.ncbi.nlm.nih.gov/34906192/)). Associated cardiac findings include interatrial septal aneurysm, ASD, and tricuspid valve prolapse.
- **Respiratory failure (severe allelic-series end):** at the geleophysic dysplasia end of the *LTBP3* spectrum, de novo heterozygous variants caused "two unrelated GD individuals who had died in early childhood from respiratory failure" ([PMID: 27068007](https://pubmed.ncbi.nlm.nih.gov/27068007/)) — a distinct, more severe LTBP3-related disorder, not classic DASS, but defining the lethal extreme of the gene's phenotypic range.

**Mechanistic prognostic insight:** Spinal deformity may adversely influence aortic biomechanics — "a spinal deformity either remains or is exacerbated in the absence of LTBP-3 and seems to adversely affect the axial mechanical properties of the thoracic aorta" ([PMID: 30306291](https://pubmed.ncbi.nlm.nih.gov/30306291/)).

**Morbidity, disability, and quality of life:** Chronic dental morbidity and psychosocial impact predominate; functional difficulties (pain, eating) and psychosocial concerns (bullying, low self-confidence) are age-dependent ([PMID: 42113459](https://pubmed.ncbi.nlm.nih.gov/42113459/)). With restorative dental care, satisfaction and function improve markedly.

**Prognostic factors:** presence and rate of aortic dilatation; severity of dental involvement; skeletal deformity. **Prognostic biomarkers:** none validated; aortic diameter on serial imaging is the practical prognostic marker for cardiovascular risk.

---

## 12. Treatment

**No disease-modifying/curative or gene-directed therapy exists.** Management is **symptomatic and multidisciplinary.**

**Dental / restorative (first-line for the AI component):**
- **Single-tooth ceramic crowns** are now recommended as first choice with high success across AI types — "single-tooth ceramic crowns should be the first choice of treatment" ([PMID: 38909645](https://pubmed.ncbi.nlm.nih.gov/38909645/)).
- **Resin composite restorations** for mild/hypoplastic cases.
- Restorative therapy relieves symptoms — "In young patients with AI symptoms of pain and hypersensitivity decreased, and aesthetics were improved following all types of restorative therapy" ([PMID: 38909645](https://pubmed.ncbi.nlm.nih.gov/38909645/)).
- Severe cases: "AI is frequently accompanied by unesthetic appearance, open bite deformity and malocclusion, a multidisciplinary approach is often required" — combined orthodontic + orthognathic surgical + prosthodontic rehabilitation over several years ([PMID: 23811667](https://pubmed.ncbi.nlm.nih.gov/23811667/)).
- Suggested NCIT: dental restoration procedure; dental crown; orthognathic surgery; prosthodontic rehabilitation.

**Cardiovascular:** Echocardiographic/imaging **surveillance** for thoracic aortic aneurysm; standard aneurysm management (blood-pressure control, activity guidance, and surgical repair when indicated) is warranted given the documented TAAD risk ([PMID: 34906192](https://pubmed.ncbi.nlm.nih.gov/34906192/)).

**Growth/endocrine:** Growth monitoring; management of short stature is supportive.

**Supportive/rehabilitative:** Pain management, nutrition support (eating difficulties), and psychosocial support for the QoL burden.

**Pharmacogenomics, gene therapy, cell therapy, RNA-based therapy, targeted therapy, immunotherapy:** **None available/applicable** at present.

**Experimental treatments:** No disease-specific registered clinical trials identified. Given the TGF-β mechanism, TGF-β pathway modulation is a conceptual (unproven) avenue.

**Personalized medicine:** Care is tailored to individual phenotype severity (dental, skeletal, cardiovascular), but no genotype-guided pharmacotherapy exists.

---

## 13. Prevention

**No primary prevention** of the underlying genetic cause is possible. Prevention is **reproductive and secondary/tertiary.**

**Reproductive/genetic prevention:**
- **Genetic counseling** for affected families, emphasizing the 25% recurrence risk in autosomal recessive inheritance.
- **Carrier and cascade testing**, especially in consanguineous families and founder populations — carrier-state evaluation "in the particular community" is a documented strategy ([PMID: 37394436](https://pubmed.ncbi.nlm.nih.gov/37394436/)).
- **Prenatal diagnosis** and **preimplantation genetic testing (PGT)** for known familial *LTBP3* variants. The pathway is illustrated in analogous AR consanguineous skeletal dysplasias: "Both parents were heterozygous carriers. Following genetic counseling, the family opted for pregnancy termination" ([PMID: 40368527](https://pubmed.ncbi.nlm.nih.gov/40368527/)).

**Secondary/tertiary prevention:**
- Early dental restorative intervention to prevent tooth breakdown, pain, and secondary caries.
- Echocardiographic aortic surveillance to enable timely intervention and **prevent aortic dissection**.
- Orthodontic/orthognathic planning to prevent progressive malocclusion complications.

**Immunization, public-health, and environmental interventions:** Not applicable (non-infectious, non-environmental genetic disorder).

---

## 14. Other Species / Natural Disease

**Taxonomy / model species:** *Mus musculus* (NCBI Taxon 10090) is the principal model species.
**Orthologous gene:** mouse *Ltbp3* (NCBI Gene ID 16997) is orthologous to human *LTBP3* (NCBI Gene ID 4054); the protein is evolutionarily conserved across vertebrates.
**Natural disease in other species:** **None catalogued.** No naturally occurring *LTBP3*-equivalent disease has been reported in companion animals or livestock (e.g., in OMIA). Veterinary relevance is therefore currently nil.
**Comparative biology:** The *Ltbp3*-null mouse demonstrates strong cross-species conservation of the disease mechanism (skeletal, craniofacial, and enamel phenotypes recapitulated).
**Transmission / zoonotic potential:** Not applicable (non-infectious genetic disorder).
**Breed (VBO):** Not applicable.

---

## 15. Model Organisms

**Principal model:** the constitutive **_Ltbp3_-knockout (null) mouse** ("we generated Ltbp-3 null mice," [PMID: 15878314](https://pubmed.ncbi.nlm.nih.gov/15878314/)). Model type: mammalian, genetic knockout (MGI).

**Phenotype recapitulation:**

| Human DASS feature | Mouse *Ltbp3*-null phenotype | Source |
|---|---|---|
| Short stature | Reduced body size | [PMID: 15878314](https://pubmed.ncbi.nlm.nih.gov/15878314/) |
| Craniofacial/skull-base anomalies | Early ossification of skull-base synchondroses; craniofacial abnormalities | [PMID: 15878314](https://pubmed.ncbi.nlm.nih.gov/15878314/) |
| Altered bone | Osteopetrosis-like high bone mass; decreased bone turnover; persistent cartilage remnants | [PMID: 15878314](https://pubmed.ncbi.nlm.nih.gov/15878314/) |
| Amelogenesis imperfecta | Very thin to absent enamel in incisors and molars | [PMID: 25669657](https://pubmed.ncbi.nlm.nih.gov/25669657/) |

"the mutant mice displayed very thin to absent enamel in both incisors and molars, hereby recapitulating the AI phenotype in the human disorder" ([PMID: 25669657](https://pubmed.ncbi.nlm.nih.gov/25669657/)). The skeletal mechanism was proposed as: "lack of Ltbp-3 results in decreased levels of TGF-beta in bone and cartilage, which leads to compromised osteoclast function and decreased bone turnover" ([PMID: 15878314](https://pubmed.ncbi.nlm.nih.gov/15878314/)).

**Mechanistic model use:** The *Ltbp3*-null mouse, crossed into fibrillin-1-deficient (Marfan) mice, has been central to dissecting LTBP3's role in TGF-β-driven aortic disease — "we genetically suppressed Ltbp3 expression in a mouse model of progressively severe MFS" ([PMID: 26494287](https://pubmed.ncbi.nlm.nih.gov/26494287/)). Strikingly, in that context "MFS mice lacking LTBP-3 have improved survival, essentially no aneurysms, reduced disruption and fragmentation of medial elastic fibers, and decreased Smad2/3 and Erk1/2 activation in their aortas" ([PMID: 26494287](https://pubmed.ncbi.nlm.nih.gov/26494287/)).

**Model limitations:** The knockout is a complete null, whereas human DASS arises from hypomorphic/LOF alleles that may retain residual function; species differences in tooth continuous growth (mouse incisors) and skeletal proportion limit direct translation of some features; the human cardiovascular (TAAD) phenotype is best studied in sensitized (Marfan) backgrounds rather than in *Ltbp3*-null mice alone.

**Applications:** Study of enamel biomineralization, skull-base/vertebral development, bone turnover, and TGF-β regulation in aortic biology.
**Other model systems:** In vitro biochemical studies of latent-complex assembly and fibrillin-1 microfibril targeting complement the mouse ([PMID: 26494287](https://pubmed.ncbi.nlm.nih.gov/26494287/)).

---

## Mechanistic Model / Interpretation

DASS is best understood as a **TGF-β "delivery/localization" disorder**. LTBP-3 does not itself signal; it is a molecular chaperone/scaffold that secures the latent TGF-β complex to the fibrillin-1 microfibrillar network of the extracellular matrix. When LTBP-3 is absent (biallelic LOF), latent TGF-β is not properly secreted or deposited in the ECM, so its **spatiotemporal availability for activation is disturbed**. Because TGF-β is a master regulator of skeletal, dental, and vascular ECM homeostasis, a single upstream lesion fans out into three phenotypic branches — enamel/dentin (ameloblast/odontoblast dysfunction), the growth skeleton (osteoclast-driven low bone turnover, premature synchondrosis ossification), and the aortic wall (elastic-fiber fragmentation → aneurysm).

Crucially, the *LTBP3* **allelic series** demonstrates that gene dosage and variant mechanism dictate the phenotype:

| Genotype / mechanism | Disorder | Inheritance | Severity |
|---|---|---|---|
| Biallelic loss of function | DASS (brachyolmia–AI) | Autosomal recessive | Chronic; dental/skeletal; aortic risk |
| Monoallelic missense (e.g., p.Ser696Cys) | Acromicric dysplasia | Autosomal dominant | Short stature, no AI |
| De novo heterozygous (splice / stop-loss) | Geleophysic dysplasia | Sporadic/dominant | Lethal (early respiratory failure) |

This dose/mechanism dependence mirrors the paradoxical mouse aortic data, in which *removing* Ltbp3 in a Marfan background *improves* aortic disease — underscoring that LTBP-3's net effect on TGF-β signaling is **context-dependent**, promoting disease in some tissues while its loss drives disease in others.

---

## Evidence Base

| PMID | Title (abbrev.) | Role in this report |
|---|---|---|
| [25669657](https://pubmed.ncbi.nlm.nih.gov/25669657/) | *LTBP3 mutations cause brachyolmia with AI* | Landmark gene-discovery paper; defines triad, causal LOF variants, mouse enamel recapitulation, ameloblast/odontoblast expression |
| [35352826](https://pubmed.ncbi.nlm.nih.gov/35352826/) | *Expanding genotypic/phenotypic spectrums of LTBP3 in DASS* | DASS name + OMIM 601216; latent-complex failure mechanism; aortic features |
| [30887145](https://pubmed.ncbi.nlm.nih.gov/30887145/) | *Genotype-phenotype correlation in LTBP3 disorders* | Core biallelic-LOF-vs-monoallelic-missense principle |
| [27068007](https://pubmed.ncbi.nlm.nih.gov/27068007/) | *LTBP3 in acromicric and geleophysic dysplasia* | Allelic series; lethal respiratory outcome; microfibrillar-network positioning |
| [15878314](https://pubmed.ncbi.nlm.nih.gov/15878314/) | *Osteopetrosis-like phenotype in Ltbp3-deficient mice* | Mouse model; skeletal/craniofacial recapitulation; TGF-β/osteoclast mechanism |
| [26494287](https://pubmed.ncbi.nlm.nih.gov/26494287/) | *LTBP-3 contribution to thoracic aneurysm in Marfan* | Latent-complex biology; SMAD2/3 + ERK1/2; context-dependent aortic role |
| [34906192](https://pubmed.ncbi.nlm.nih.gov/34906192/) | *Novel LTBP3 mutations in TAAD* | Links biallelic LTBP3 loss to thoracic aortic aneurysm/dissection |
| [8721563](https://pubmed.ncbi.nlm.nih.gov/8721563/) | *New skeletal dysplasia with AI and platyspondyly* | Original clinical delineation; AR inheritance; skeletal hallmarks |
| [32432408](https://pubmed.ncbi.nlm.nih.gov/32432408/) | *Bi-allelic LTBP3 variants — first Indian patient* | Ultra-rarity (20 individuals/9 families); consistent phenotype |
| [35998423](https://pubmed.ncbi.nlm.nih.gov/35998423/) | *LTBP3 variants in two Moroccan families* | Novel variants; nephrocalcinosis; intra-familial severity variation |
| [37394436](https://pubmed.ncbi.nlm.nih.gov/37394436/) | *LTBP3 variant in Druze Arab patients* | Founder variant; homozygosity mapping; carrier-screening strategy |
| [2669482](https://pubmed.ncbi.nlm.nih.gov/2669482/) | *Brachyolmia heterogeneity* | Differential diagnosis; genetic heterogeneity of brachyolmia |
| [38909645](https://pubmed.ncbi.nlm.nih.gov/38909645/) | *Clinical management of AI* | First-line ceramic crowns; QoL burden; restorative outcomes |
| [23811667](https://pubmed.ncbi.nlm.nih.gov/23811667/) | *Multidisciplinary management of AI* | Multidisciplinary orthodontic/orthognathic/prosthodontic care |
| [42113459](https://pubmed.ncbi.nlm.nih.gov/42113459/) | *Condition-specific PROM for AI* | Age-dependent QoL impact data |
| [30306291](https://pubmed.ncbi.nlm.nih.gov/30306291/) | *LTBP-3 and spinal effects on aorta in Marfan* | Spinal deformity → aortic mechanics link |
| [40368527](https://pubmed.ncbi.nlm.nih.gov/40368527/) | *Prenatal diagnosis of Desbuquois dysplasia* | Analog reproductive-prevention pathway for AR consanguineous dysplasia |

---

## Limitations and Knowledge Gaps

1. **Very small evidence base.** The entire human literature comprises small consanguineous family series (~20+ individuals as of 2020). Precise prevalence, incidence, penetrance quantification, and natural-history data are not available.
2. **Cardiovascular risk quantification.** The magnitude and age-dependence of TAAD risk in biallelic DASS patients (vs. heterozygous carriers) is not established; systematic aortic surveillance data are lacking.
3. **Renal involvement.** Nephrocalcinosis was reported in Moroccan families but its frequency and significance across the disorder are unclear.
4. **Genotype–phenotype granularity.** While the biallelic-LOF vs monoallelic-missense dichotomy is established, finer correlations (which alleles predict aortic risk, dental severity, nephrocalcinosis) are unknown.
5. **No human tissue omics.** Transcriptomic/proteomic/metabolomic profiling of patient tissues has not been reported; mechanistic inference relies heavily on the mouse and on aortic (Marfan-background) studies.
6. **No modifiers or epigenetics.** Disease modifiers and any epigenetic contributions are unstudied.
7. **Context-dependence unresolved.** The paradox that Ltbp3 removal *ameliorates* aortic disease in Marfan mice while biallelic loss *causes* aortic disease in humans is not fully reconciled.
8. **No therapeutics pipeline.** No disease-specific trials or targeted therapies exist.

---

## Proposed Follow-up Experiments / Actions

1. **Establish an international DASS/*LTBP3* patient registry** to define prevalence, penetrance, expressivity, and natural history, with standardized dental, skeletal, renal, and cardiovascular phenotyping.
2. **Prospective aortic surveillance study** in molecularly confirmed biallelic and heterozygous *LTBP3* individuals to quantify TAAD risk, define surveillance intervals, and set intervention thresholds.
3. **Variant functional assays** (latent-complex assembly, fibrillin-1 targeting, SMAD2/3 and ERK1/2 readouts) for all reported variants to refine ACMG classification and genotype–phenotype correlation, including the missense p.Cys1239Tyr.
4. **Conditional/tissue-specific *Ltbp3* mouse models** (ameloblast-, osteoclast-, and vascular-smooth-muscle-specific knockouts) and hypomorphic knock-ins to dissect branch-specific mechanisms and reconcile the context-dependent aortic paradox.
5. **Patient-derived models** (iPSC-derived ameloblast/odontoblast organoids; iPSC-derived vascular smooth muscle) to study enamel and aortic pathology in a human genetic background.
6. **Multi-omics of patient tissues/serum** (transcriptomics, proteomics of ECM/TGF-β components) to identify diagnostic and prognostic biomarkers of aortic risk.
7. **TGF-β pathway pharmacology screen** in models to evaluate whether pathway modulation (e.g., losartan-type ARBs used in Marfan) mitigates aortic and/or skeletal features.
8. **Founder-population carrier screening programs** (e.g., Druze Arab communities) coupled with genetic counseling and PGT access to reduce recurrence.
9. **Prospective QoL/PROM study** specific to DASS integrating dental, growth, and psychosocial outcomes across the lifespan.

---

*Report compiled from 17 primary sources across 5 investigative iterations. Evidence source types: human clinical (case/family series), model organism (Ltbp3-null and Marfan-cross mouse), in vitro biochemistry (latent-complex/fibrillin studies), and computational (molecular modeling of missense variants).*


## Artifacts

- [OpenScientist final report](Brachyolmia-Amelogenesis_Imperfecta_Syndrome-deep-research-openscientist_artifacts/final_report.html)
- [OpenScientist final report](Brachyolmia-Amelogenesis_Imperfecta_Syndrome-deep-research-openscientist_artifacts/final_report.pdf)

## Reference Validation

Checked with `linkml-reference-validator` 0.2.1.

| Outcome | Count |
| --- | --- |
| References checked | 17 |
| Resolved | 17 |
| Unresolved (possible confabulation) | 0 |
| Unverifiable | 0 |
| Quoted claims checked | 28 |
| Quoted claims found in source | 28 |
| Quoted claims **not** found in source | 0 |
| References weighed for topical relevance | 17 |
| On topic | 9 |
| Off topic | 0 |

All extracted references resolved successfully.

## Term Validation

Checked with `linkml-term-validator` 0.4.5, through the `ols:` adapter.

| Outcome | Count |
| --- | --- |
| Terms checked | 35 |
| Resolved | 34 |
| Unresolved (possible confabulation) | 0 |
| Obsolete | 0 |
| Unverifiable | 1 |
| Terms whose name was checked | 10 |
| Terms named correctly | 7 |
| Terms named as a **different** term | 1 |
| Terms whose name is worth a second look | 2 |

### Terms the report names something else

These identifiers resolve, so nothing about them looks wrong, and the ontology calls them something unrelated to what the report calls them. That usually means the identifier is not the one the sentence needs:

- `HP:0012865` (1 mention) - the report calls it "Broad femoral neck"; HP calls it **Abnormal sperm head morphology**

### Terms whose name is worth a second look

The report's name for these is recognisably related to the term's own name without being one of them. A loose paraphrase reads the same way as a citation of the wrong sibling term - and so does a *related* synonym, which the ontology records precisely because it names something adjacent rather than the same thing - so these are listed rather than judged:

- `HP:0000679` (1 mention) - the report calls it "Taurodontism"; HP calls it **Taurodontia**, and lists "Taurodontism" among its other names
- `HP:0011063` (1 mention) - the report calls it "Abnormal dentin morphology"; HP calls it **Abnormal incisor morphology**